Hemispherx BioPharma Company Profile (NYSE:HEB)

About Hemispherx BioPharma (NYSE:HEB)

Hemispherx BioPharma logoHemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSE:HEB
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: $14.14 million
  • Outstanding Shares: 26,186,000
Average Prices:
  • 50 Day Moving Avg: $0.60
  • 200 Day Moving Avg: $0.65
  • 52 Week Range: $0.39 - $2.64
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $92,000.00
  • Price / Sales: 153.70
  • Book Value: $0.64 per share
  • Price / Book: 0.84
Profitability:
  • EBIDTA: ($12,500,000.00)
Misc:
  • Average Volume: 240,857 shs.
  • Short Ratio: 2.88
 

Frequently Asked Questions for Hemispherx BioPharma (NYSE:HEB)

What is Hemispherx BioPharma's stock symbol?

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "HEB."

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSE:HEB) posted its quarterly earnings data on Monday, August, 15th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business earned $0.02 million during the quarter. During the same quarter in the prior year, the business posted ($0.02) EPS. View Hemispherx BioPharma's Earnings History.

Are investors shorting Hemispherx BioPharma?

Hemispherx BioPharma saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 645,892 shares, a decrease of 6.5% from the April 28th total of 690,823 shares. Based on an average daily trading volume, of 163,594 shares, the short-interest ratio is presently 3.9 days. Approximately 2.6% of the company's stock are sold short.

Who are some of Hemispherx BioPharma's key competitors?

How do I buy Hemispherx BioPharma stock?

Shares of Hemispherx BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Hemispherx BioPharma stock cost?

One share of Hemispherx BioPharma stock can currently be purchased for approximately $0.54.

Analyst Ratings

Consensus Ratings for Hemispherx BioPharma (NYSE:HEB) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Hemispherx BioPharma (NYSE:HEB)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Hemispherx BioPharma (NYSE:HEB)
Earnings by Quarter for Hemispherx BioPharma (NYSE:HEB)
Earnings History by Quarter for Hemispherx BioPharma (NYSE:HEB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q3 16($0.30)$0.02 millionViewN/AView Earnings Details
8/15/2016Q216($0.01)$0.02 millionViewN/AView Earnings Details
5/16/2016Q116($0.01)$40.99 million$0.04 millionViewN/AView Earnings Details
8/13/2015Q2($0.02)$0.05 millionViewN/AView Earnings Details
5/13/2015Q1 15($0.02)$0.04 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.03)ViewN/AView Earnings Details
11/5/2012Q312($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hemispherx BioPharma (NYSE:HEB)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $-0.03 EPS

Dividends

Dividend History for Hemispherx BioPharma (NYSE:HEB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Hemispherx BioPharma (NYSE:HEB)
Insider Trades by Quarter for Hemispherx BioPharma (NYSE:HEB)
Insider Trades by Quarter for Hemispherx BioPharma (NYSE:HEB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/2/2017Adam PascaleCFOBuy15,873$0.63$9,999.99View SEC Filing  
5/2/2017David R StrayerInsiderBuy7,937$0.63$5,000.31View SEC Filing  
4/27/2017Thomas K EquelsCEOBuy72,464$0.69$50,000.16View SEC Filing  
4/11/2017Thomas K EquelsCEOBuy200,000$0.50$100,000.00View SEC Filing  
2/16/2017Adam PascaleCFOBuy6,981$0.46$3,211.26View SEC Filing  
2/16/2017David R StrayerInsiderBuy9,892$0.46$4,550.32View SEC Filing  
2/16/2017Wayne S SpringateSVPBuy8,014$0.46$3,686.44View SEC Filing  
12/22/2016Thomas K EquelsCEOBuy68,493$0.73$49,999.89View SEC Filing  
11/1/2016Thomas K EquelsCEOBuy10,000$1.00$10,000.00View SEC Filing  
7/8/2016Thomas K EquelsCEOBuy48,000$0.12$5,760.00View SEC Filing  
7/1/2016Thomas K EquelsCEOBuy171,000$0.12$20,520.00View SEC Filing  
3/18/2016Thomas K EquelsCEOBuy30,000$0.13$3,900.00View SEC Filing  
3/11/2016Thomas K EquelsCEOBuy40,000$0.16$6,400.00View SEC Filing  
3/10/2016Thomas K EquelsCEOBuy30,000$0.16$4,800.00View SEC Filing  
8/20/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/18/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/17/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/14/2015Thomas K EquelsCFOBuy79,104$0.18$14,238.72View SEC Filing  
4/28/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/27/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/21/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/20/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/17/2015William A CarterCEOBuy73,681$0.23$16,946.63View SEC Filing  
4/16/2015William A CarterCEOBuy26,319$0.23$6,053.37View SEC Filing  
4/15/2015Thomas K EquelsCFOBuy100,000$0.23$23,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Hemispherx BioPharma (NYSE:HEB)
Latest Headlines for Hemispherx BioPharma (NYSE:HEB)
Source:
DateHeadline
americanbankingnews.com logoShort Interest in Hemispherx BioPharma, Inc (HEB) Drops By 6.5%
www.americanbankingnews.com - May 25 at 7:12 AM
rttnews.com logoEARNINGS SUMMARY: Details of Hemispherx Biopharma, Inc. Q1 Earnings Report
www.rttnews.com - May 16 at 11:24 AM
finance.yahoo.com logoHemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017
finance.yahoo.com - May 16 at 11:24 AM
americanbankingnews.com logoHemispherx BioPharma, Inc (HEB) Short Interest Update
www.americanbankingnews.com - May 9 at 6:28 PM
finance.yahoo.com logoETFs with exposure to Hemispherx Biopharma, Inc. : May 8, 2017
finance.yahoo.com - May 8 at 5:20 PM
americanbankingnews.com logoHemispherx BioPharma (HEB) Earns Media Impact Rating of -0.10
www.americanbankingnews.com - May 4 at 7:14 PM
americanbankingnews.com logoHemispherx BioPharma (HEB) Receiving Somewhat Critical Press Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 3:47 PM
americanbankingnews.com logoHemispherx BioPharma (HEB) Getting Somewhat Negative News Coverage, Study Finds
www.americanbankingnews.com - April 27 at 6:32 PM
americanbankingnews.com logoHemispherx BioPharma, Inc (HEB) CEO Buys $50,000.16 in Stock
www.americanbankingnews.com - April 27 at 6:08 PM
finance.yahoo.com logoETFs with exposure to Hemispherx Biopharma, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 5:31 PM
americanbankingnews.com logoPositive Press Coverage Likely to Impact Hemispherx BioPharma (HEB) Share Price
www.americanbankingnews.com - April 16 at 3:00 PM
americanbankingnews.com logoHemispherx BioPharma (HEB) Earning Somewhat Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 13 at 7:21 PM
americanbankingnews.com logoHemispherx BioPharma, Inc (HEB) Short Interest Up 7.8% in March
www.americanbankingnews.com - April 12 at 7:17 AM
americanbankingnews.com logoInsider Buying: Hemispherx BioPharma, Inc (HEB) CEO Purchases 200,000 Shares of Stock
www.americanbankingnews.com - April 11 at 1:57 PM
finance.yahoo.com logoEdited Transcript of HEB earnings conference call or presentation 7-Apr-17 3:00pm GMT
finance.yahoo.com - April 8 at 9:21 AM
finance.yahoo.com logoETFs with exposure to Hemispherx Biopharma, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 5:32 PM
finance.yahoo.com logoHemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
finance.yahoo.com - April 7 at 10:14 AM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
biz.yahoo.com - April 3 at 6:25 PM
globenewswire.com logoHemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016 - GlobeNewswire (press release)
globenewswire.com - April 2 at 6:15 AM
finance.yahoo.com logoHemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016
finance.yahoo.com - April 1 at 12:47 PM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 31 at 5:41 PM
americanbankingnews.com logoHemispherx BioPharma, Inc (HEB) Short Interest Down 8.4% in February
www.americanbankingnews.com - March 10 at 9:03 AM
benzinga.com logoFamily Office Legend Thomas Gütermann Talks To The Media For The First Time Ever: 'We Opened A Fund Focused ... - Benzinga
www.benzinga.com - March 3 at 10:46 PM
bizjournals.com logo$1M deal: Hemispherx plans to sell stock, warrants
www.bizjournals.com - February 3 at 6:08 PM
us.rd.yahoo.com logoHemispherx Biopharma, Inc. Announces $1 Million Registered Direct Offering
us.rd.yahoo.com - February 2 at 6:15 PM
us.rd.yahoo.com logo8:31 am Hemispherx Biopharma announces $1 mln registered direct offering at $0.55/share
us.rd.yahoo.com - February 2 at 6:15 PM
finance.yahoo.com logoHemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe
finance.yahoo.com - January 26 at 7:11 PM
finance.yahoo.com logo10:52 am Hemispherx Biopharma announces an order of newly manufactured rintatolimod (Ampligen) for sale utilizing the Early Access Program in Europe has been shipped with receipt confirmed on January 26
finance.yahoo.com - January 26 at 7:11 PM
biz.yahoo.com logoHEMISPHERX BIOPHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh
biz.yahoo.com - January 17 at 8:40 PM
finance.yahoo.com logoHemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
finance.yahoo.com - January 11 at 6:14 PM

Social

Chart

Hemispherx BioPharma (HEB) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff